RxDoctor Payments Data

Gretchen Farmer, MD

Internal Medicine · Union, MONPI 1720283450

Payments from drug & device makers

$6,293in general payments, 2019–2025

Across 354 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$966
  • AstraZeneca$438
  • Pfizer$336
  • Boehringer Ingelheim$295
  • Supernus Pharmaceuticals, Inc.$284
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,21699%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,293 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$41,020
Medicare patients
80
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$256,677
JardianceEmpagliflozin215$205,438
EliquisApixaban90$82,123
RybelsusSemaglutide38$63,655
XareltoRivaroxaban47$50,831
MounjaroTirzepatide46$48,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$46,890
JanuviaSitagliptin Phosphate25$30,212
MyrbetriqMirabegron31$22,311
Tresiba Flextouch U-100Insulin Degludec41$20,732
Tresiba Flextouch U-200Insulin Degludec18$18,948
EntrestoSacubitril/Valsartan32$16,366
WegovySemaglutide12$16,266
FarxigaDapagliflozin Propanediol18$14,427
SymbicortBudesonide/Formoterol Fumarate21$9,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$966$336,597213 claims
Boehringer IngelheimJardiance$295$205,438215 claims
PfizerEliquis, Premarin$336$89,193112 claims
Lilly USA, LLCMounjaro, Cymbalta$283$55,12258 claims
GSKTrelegy Ellipta, Arexvy$225$54,81579 claims
Johnson & JohnsonXarelto$30$50,83147 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$438$32,57652 claims
MerckJanuvia$65$30,21225 claims
Astellas Pharma US IncMyrbetriq$19$22,31131 claims
NovartisEntresto$17$16,36632 claims
AbbVieSynthroid$1,328$2,38621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Union

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →